Alendronate Stimulates Osteoprotegerin Expression in Fibroblasts from Periprosthetic Membrane
暂无分享,去创建一个
Xianlong Zhang | Yao Jiang | Qi Wang | Hao Shen | B. Zeng | Qiaojie Wang | Yunsu Chen | Y. Qian
[1] Xianlong Zhang,et al. Substance P enhanced titanium particles-induced RANKL expression in fibroblasts from periprosthetic membrane , 2013, Connective tissue research.
[2] D. Tipton,et al. Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. , 2011, Journal of periodontal research.
[3] E. Schwarz,et al. Differential effects of biologic versus bisphosphonate inhibition of wear debris‐induced osteolysis assessed by longitudinal micro‐CT , 2008, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[4] Xianlong Zhang,et al. Substance P stimulates production of interleukin 1beta and tumor necrosis factor alpha in fibroblasts from hip periprosthetic membrane. , 2008, The Journal of arthroplasty.
[5] Xianlong Zhang,et al. Substance P augments PGE2 and IL-6 production in titanium particles-stimulated fibroblasts from hip periprosthetic membrane. , 2007, Journal of biomedical materials research. Part A.
[6] T. Glant,et al. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. , 2006, Arthritis and rheumatism.
[7] Yong Zhou,et al. Effects of bone cement particles on the function of pseudocapsule-derived fibroblasts , 2006, Acta orthopaedica.
[8] I. Martin,et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. , 2005, Biomaterials.
[9] S. Santavirta,et al. Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. , 2005, Journal of biomedical materials research. Part B, Applied biomaterials.
[10] E. Schwarz,et al. Fibroblasts Express RANKL and Support Osteoclastogenesis in a COX‐2‐Dependent Manner After Stimulation With Titanium Particles , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] S. Santavirta,et al. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. , 2005, The Journal of rheumatology.
[12] P. J. Drury,et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. , 2004, Bone.
[13] J. Rodriguez-Portales,et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.
[14] H. Zreiqat,et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. , 2004, Biomaterials.
[15] Chia-Chen Hsu,et al. The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. , 2003, The Journal of bone and joint surgery. American volume.
[16] S. Santavirta,et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. , 2003, The Journal of bone and joint surgery. British volume.
[17] W. Maksymowych. Bisphosphonates for arthritis--a confusing rationale. , 2003, The Journal of rheumatology.
[18] J. Devogelaer. New uses of bisphosphonates: osteogenesis imperfecta. , 2002, Current opinion in pharmacology.
[19] J. Jurvelin,et al. Effect of Alendronate on Periprosthetic Bone Loss After Total Knee Arthroplasty: A One-Year, Randomized, Controlled Trial of 19 Patients , 2002, Calcified Tissue International.
[20] Kirk E. Smith,et al. Recombinant Adeno-Associated Virus-Mediated Osteoprotegerin Gene Therapy Inhibits Wear Debris-Induced Osteolysis , 2002, The Journal of bone and joint surgery. American volume.
[21] C. Christiansen,et al. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products , 2002, Annals of the rheumatic diseases.
[22] E. Schwarz,et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[23] A. Boskey,et al. In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[24] Y. Iwamoto,et al. Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells , 2002, Annals of the rheumatic diseases.
[25] P. Aspenberg,et al. Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats , 2002, Acta orthopaedica Scandinavica.
[26] J. Jurvelin,et al. Alendronate Reduces Periprosthetic Bone Loss After Uncemented Primary Total Hip Arthroplasty: A Prospective Randomized Study , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] Safdar N. Khan,et al. Bisphosphonate Therapy in Fibrous Dysplasia , 2001, Clinical orthopaedics and related research.
[28] J. Ingle,et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. , 2000, Cancer research.
[29] T. Martin,et al. Therapeutic approaches to bone diseases. , 2000, Science.
[30] D. Murray,et al. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages , 2000, Annals of the rheumatic diseases.
[31] G. Passeri,et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. , 1998, Bone.
[32] G. Golomb,et al. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors , 1998, Journal of cellular biochemistry.
[33] H. Rubash,et al. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. , 1997, Clinical orthopaedics and related research.
[34] C. Trevisan,et al. Bisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases. , 2013, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[35] Francesca Gimigliano,et al. Periprosthetic bone density as outcome of therapeutic response. , 2010, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.
[36] 三谷 誠. Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts , 2005 .
[37] K. Goa,et al. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. , 2003, Drugs.